Microbiological diagnosis of pleural infections: a comparative evaluation of a novel syndromic real-time PCR panel

Autor: Øyvind Kommedal, Tomas Mikal Eagan, Øystein Fløtten, Truls Michael Leegaard, William Siljan, Hilde Fardal, Bjørnar Bø, Fredrik Grøvan, Kjersti Wik Larssen, Arne Kildahl-Andersen, Reidar Hjetland, Rune Tilseth, Sølvi Kristine Øyen Hareide, Marit Tellevik, Ruben Dyrhovden

Publikováno v: Microbiology Spectrum, Vol 12, Iss 6 (2024)

ABSTRACT Current microbial diagnostics for pleural infections are insufficient. Studies using 16S targeted next-generation sequencing report that only 10%–16% of bacteria present are cultured and that 50%–78% of pleural fluids containing relevant

Externí odkaz: https://doaj.org/article/e5a9532629984d69aed935374c21cec5

Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC

Autor: Kristin Stokke, Sveinung Sørhaug, Sunil Xavier Raj, Bjørn Henning Grønberg, Tesfaye Madebo, Kristin Toftaker Killingberg, Nina Helbekkmo, Odd Terje Brustugun, Kjersti Hornslien, Tarje Onsøien Halvorsen, Sverre Fluge, Øystein Fløtten

Publikováno v: Acta Oncologica. 59:1051-1057

Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squa...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01faf9c7db95b770a961dec337c748bb
https://doi.org/10.1080/0284186x.2020.1778179

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer:an open-label, randomised, phase 2 trial

Autor: Jens Engleson, Kristin Toftaker Killingberg, Georgios Tsakonas, Tesfaye Madebo, Øystein Fløtten, Seppo W. Langer, Odd Terje Brustugun, Signe Risum, Bjørn Henning Grønberg, Jan Nyman, Tarje Onsøien Halvorsen, Tine Schytte, Kjersti Hornslien

Publikováno v: Grønberg, B H, Killingberg, K T, Fløtten, Ø, Brustugun, O T, Hornslien, K, Madebo, T, Langer, S W, Schytte, T, Nyman, J, Risum, S, Tsakonas, G, Engleson, J & Halvorsen, T O 2021, ' High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer : an open-label, randomised, phase 2 trial ', Lancet Oncology, vol. 22, no. 3, pp. 321-331 . https://doi.org/10.1016/S1470-2045(20)30742-7
Grønberg, B H, Killingberg, K T, Fløtten, Ø, Brustugun, O T, Hornslien, K, Madebo, T, Langer, S W, Schytte, T, Nyman, J, Risum, S, Tsakonas, G, Engleson, J & Halvorsen, T O 2021, ' High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer : an open-label, randomised, phase 2 trial ', The Lancet Oncology, vol. 22, no. 3, pp. 321-331 . https://doi.org/10.1016/S1470-2045(20)30742-7

BACKGROUND: Concurrent chemoradiotherapy is standard treatment for limited stage small-cell lung cancer (SCLC). Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions is considered to be the most effective schedule. The aim of this study was to i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1afdfffff1dfd163eae55d2c4e62564
https://curis.ku.dk/ws/files/333701537/High_dose_TRT_in_LS_SCLC_Gronberg_050920_002_.pdf

Muscle mass and association to quality of life in non-small cell lung cancer patients

Autor: Tore Wentzel-Larsen, Roy M. Bremnes, Bjørg Sjøblom, Bjørn Henning Grønberg, Øystein Fløtten, Nina Aass, Marianne Jensen Hjermstad, Vickie E. Baracos, Marit S. Jordhøy, Asta Bye

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle. 8:759-767

Background Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) and selected Qo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85c7a2b4d888f753bb0b4031be482d27
https://doi.org/10.1002/jcsm.12206

Oral versus intravenous vinorelbine in advanced NSCLC—a retrospective comparison

Autor: Øystein Fløtten, Roy M. Bremnes, Christian von Plessen, Nina Helbekkmo, Stein Sundstrøm, Bjørn Henning Grønberg

Publikováno v: Fløtten, O, Grønberg, B H, Sundstrøm, S H, Helbekkmo, N, Bremnes, R M & von Plessen, C 2016, ' Oral versus intravenous vinorelbine in advanced NSCLC—a retrospective comparison ', Cancer Treatment and Research Communications, vol. 9, pp. 15-20 . https://doi.org/10.1016/j.ctarc.2016.06.005

Objective Vinorelbine combined with carboplatin is one of the recommended first-line chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Vinorelbine, traditionally administered intravenously, is also available for oral administratio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8aaa4eafc7944a2dc82f864a77496c
https://doi.org/10.1016/j.ctarc.2016.06.005